Skip to main content

Advertisement

Erratum to: Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment

Article metrics

The original article was published in Orphanet Journal of Rare Diseases 2015 10:125

Erratum

Following the publication of our article “Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment” by Kampmann et al. [1] we have become aware that the dose of agalsidase alfa was not reported.

Eligible patients had a Fabry disease diagnosis confirmed by enzyme assay (males) and/or DNA analysis (males and females), were aged ≥14 years at treatment start, and had received agalsidase alfa (Replagal®; Shire, Lexington, Massachusetts, USA) ERT at a dose of 0.2 mg/kg body weight every other week for approximately 10 years.

Reference

  1. 1.

    Kampmann C, Perrin A, Beck M. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment. Orphanet J Rare Dis. 2015;10:125.

Download references

Author information

Correspondence to Christoph Kampmann.

Additional information

The online version of the original article can be found under doi:10.1186/s13023-015-0338-2.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark